Revolution Medicines Inc (RVMD) is next scheduled to report earnings on Aug 5, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-1.90.
Heading into this report, the model's fair value estimate sits 9.8% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for RVMD from 1 independent valuation methods with sufficient data. 0 place fair value above the current price of $187.50, and 1 place it below. The model-blended estimate lands at $169.18 — a model fair value differential of 9.8% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores RVMD at 34.9/100 (D+, Mixed), blending profitability, balance-sheet, and cash-flow quality. Its SAVE composite score has moved +0.4 over the past 30 days.
Revolution Medicines Inc (RVMD) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator